A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

被引：5
|
作者：
Palumbo, Antonio
Magarotto, Valeria
Bringhen, Sara
Offidani, Massimo
Pietrantuono, Giuseppe
Liberati, Anna Marina
Benevolo, Giulia
Ledda, Antonio
Gilestro, Milena
Galli, Monica
Patriarca, Francesca
Genuardi, Mariella
Giuliani, Nicola
Zambello, Renato
Zdenek, Adam
La Fauci, Alessia
Corradini, Paolo
Falcone, Antonietta Pia
Musolino, Caterina
Rossi, Davide
Caraffa, Patrizia
Musto, Pellegrino
Cavallo, Federica
Hajek, Roman
Boccadoro, Mario
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.536.536
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
536
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
    Usmani, S. Z.
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Nooka, A.
    Ervin-Haynes, A.
    Yiu, W.
    Nagarwala, Y.
    Berger, A.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Gibson, C. J.
    Facon, T.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258
  • [32] A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)
    Palumbo, A.
    Cavallo, F.
    Di Raimondo, F.
    di Toritto, T. Caravita
    Grammatico, S.
    Corradini, P.
    Omede, P.
    Ben Yehuda, D.
    Nagler, A.
    Boccadoro, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S639 - S639
  • [33] A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens
    Palumbo, Antonio
    Delforge, Michel
    Catalano, John
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Yu, Zhinuan
    Herbein, Lindsey
    Mei, Jay M.
    Jacques, Christian J.
    Dimopoulos, Meletios A.
    BLOOD, 2010, 116 (21) : 273 - 274
  • [34] PHASE 1/2 TRIAL OF LENALIDOMIDE IN COMBINATION WITH CYCLOPHOSPHAMIDE AND PREDNISONE (REP) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (REPEAT-STUDY)
    Nijhof, I. S.
    Franssen, L. E.
    Levin, M. D.
    Koene, H. R.
    Bloem, A. C.
    Beeker, A.
    Bos, G. M.
    Faber, L. M.
    Klein, S. K.
    van der Spek, E.
    Ypma, P. F.
    Raymakers, R. A.
    van Spronsen, D. J.
    Westerweel, P. E.
    Oostvogels, R.
    van Velzen, J.
    van Kessel, B.
    Mutis, T.
    Sonneveld, P.
    Zweegman, S.
    Lokhorst, H. M.
    van de Donk, N. W.
    HAEMATOLOGICA, 2016, 101 : 530 - 531
  • [35] Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Hernandez, Miguel T.
    Ocio, Enrique M.
    Rosinol, Laura
    Martinez, Rafael
    Teruel, Ana Isabel
    Gutierrez, Norma C.
    Martin, Maria-Luisa
    Oriol, Albert
    Bargay, Joan
    Bengoechea, Enrique
    Gonzalez, Yolanda
    Perez de Oteyza, Jaime
    Gironella, Mercedes
    Encinas, Cristina
    Cabrera, Carmen
    Paiva, Bruno
    Teresa Cedena, Maria
    Puig, Noemi
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesus
    BLOOD, 2015, 126 (23)
  • [36] A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients
    Palumbo, A. P.
    Cavallo, F.
    Di Raimondo, F.
    Ben Yehuda, D.
    Omade, P.
    Montefusco, V.
    Rossini, F.
    Harden, I.
    Caravita, T.
    Boccadoro, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)
    Nijhof, Inger S.
    Zweegman, Sonja
    Levin, Mark-David
    Koene, Harry R.
    Beeker, Aart
    Bloem, Andries C.
    Bos, Gerard M. J.
    Faber, Laura M.
    Klein, Saskia K.
    de Kruijf, Evert-Jan F. M.
    van der Spek, Ellen
    Wittebol, Shulamiet
    van Velzen, Jeroen F.
    van Kessel, Berris
    Mutis, Tuna
    Sonneveld, Pieter
    Lokhorst, Henk
    van de Donk, Niels W. C. J.
    BLOOD, 2013, 122 (21)
  • [38] MELPHALAN, PREDNISONE, LENALIDOMIDE (MPR) VERSUS MELPHALAN(200 MG/M2) AND AUTOLOGOUS TRANSPLANTATION (MEL200) IN NEWLY DIAGNOSED MYELOMA PATIENTS: A PHASE III TRIAL
    Palumbo, A.
    Cavallo, F.
    Hardan, I.
    Redoglia, V.
    Petrucci, M. T.
    Scollo, C.
    Corradini, P.
    Siniscalchi, A.
    Di Raimondo, F.
    Boccadoro, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 351 - 351
  • [39] Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Lewis, Philip
    Millar, Stefanie
    Zhang, Jingshan
    Mei, Jay
    Delforge, Michel
    LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1489 - 1497
  • [40] Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older
    Palumbo, A. P.
    Delforge, M.
    Catalano, J.
    Hajek, R.
    Kropff, M.
    Petrucci, M. T.
    Yu, Z.
    Mei, J. M.
    Dimopoulos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345